Hot Stock
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000 % RENDITE!!
Anzeige
IMMUTEP ADR WKN: A2H8YL ISIN: US45257L1089 Kürzel: IMMP Forum: Aktien Thema: Hauptdiskussion
1,95 USD
-1,52 %-0,03
24. Dec, 23:00:00 Uhr,
Nasdaq
Kommentare 123
N
NOFX_PC,
18.02.2020 20:04 Uhr
0
Morgen wird es nochmal interessant
N
NOFX_PC,
07.02.2020 18:19 Uhr
0
Dann im März Daten der größeren Studie.
N
NOFX_PC,
07.02.2020 18:19 Uhr
0
Ich denke krebskongress in Berlin ist hier das nächste Ziel.
Schorsch11,
29.01.2020 15:39 Uhr
0
Immutep Activities Report
January 29, 2020 08:00 ET | Source: Immutep Limited
First progression-free survival (“PFS”) data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020
More mature data expected from TACTI-002 in February 2020
Sufficiently funded to deliver key upcoming catalysts
http://www.globenewswire.com/news-release/2020/01/29/1976732/0/en/Immutep-Activities-Report.html
Schorsch11,
21.01.2020 14:18 Uhr
0
http://stocktwits.com/tripleface/message/191113215
Luke_99,
18.01.2020 0:41 Uhr
0
Zu viert! 😉 Da ist ordentlich was in der Pipeline bei Immutep!
Schorsch11,
14.01.2020 8:10 Uhr
0
http://stocktwits.com/tripleface/message/190167735
N
NOFX_PC,
12.01.2020 18:37 Uhr
0
Jupp q1 2020 ist interessant hier 😀
P
Paint,
12.01.2020 13:11 Uhr
0
Oha jetzt sind wir schon zu dritt. :) es geht Berg auf
N
NOFX_PC,
12.01.2020 12:26 Uhr
0
https://themarketherald.com.au/immutep-asximm-expands-part-c-of-tacti-002-study-due-to-positive-data-2020-01/
N
NOFX_PC,
12.01.2020 12:25 Uhr
0
https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-limiteds-asximm-shift-from-loss-to-profit/
Schorsch11,
09.01.2020 7:24 Uhr
0
http://stocktwits.com/jeremy80/message/189609071
Schorsch11,
06.01.2020 20:41 Uhr
0
Near-Term Upside In LAG-3 Immunotherapy - Buy Immutep
Summary
LAG-3 - An emerging field in immunotherapy drug development.
Immutep's 227 patient study in Metastatic Breast Cancer due to report in March 2020.
Downside protection with Big Pharma relationships and multiple clinical trials currently underway.
Undervalued stock with than US$100 million market capitalisation.
Immutep (ASX:IMM, IMMP) is an Australian primarily listed biotechnology company working primarily in the field of cancer immunotherapy using the Lymphocyte Activation Gene 3 (LAG-3) immune control mechanism.
Frederic Triebel, the Founder and Chief Scientist at Immutep, discovered in the late 1990s that a soluble protein called LAG-3 could activate dendritic cells in the vicinity of tumour
https://seekingalpha.com/article/4313526?source=ansh $IMMP
Schorsch11,
06.01.2020 20:36 Uhr
0
Prof. Dr. Salah-Eddin Al-Batran, lead investigator of INSIGHT-004 commented: "We are really pleased that INSIGHT-004 recruitment is advancing and that we can start to enroll the second cohort of 6 patients. The treatment's safety profile is consistent with previous trials of efti which is encouraging and it's also good to see early activity signals with one patient reporting a partial response already."
INSIGHT-004 is the fourth arm of the INSIGHT trial which is being conducted by Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany (IKF). It is being conducted under Immutep's collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc and is evaluating the safety, tolerability and recommended Phase II dose of Immutep's lead immunotherapy product candidate efti when given in combination with avelumab in 12 patients with advanced solid malignancies.
https://www.benzinga.com/pressreleases/19/12/g15016886/insight-004-clinical-trial-update
Schorsch11,
06.01.2020 20:33 Uhr
0
MARKET CAP 62,435,506
SHARES 34,117,763
AV. DAILY VOLUME 34,744
https://www.immutep.com/files/content/investor/investor-update/2017/2002185.pdf
112 gelistete Patente
https://patentscope.wipo.int/search/en/result.jsf?_vid=P12-K52UDX-42431
9 klinische Studien
https://clinicaltrials.gov/ct2/results?cond=&term=immutep&cntry=&state=&city=&dist=
Schorsch11,
06.01.2020 20:28 Uhr
0
Initial safety data from Phase I
INSIGHT-004
Expected in Q4 CY2019
More mature data from TACTI-002
Expected in Q1 CY2020
First data from Phase IIb AIPAC
Expected in Q1 CY2020
Final safety data from Phase I TACTI-mel
Expected in H1 CY2020
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | ATOS Hauptdiskussion | -15,15 % | |
2 | Lilium Aktie | +268,39 % | |
3 | BAYER Hauptdiskussion | -0,63 % | |
4 | BTC/USD Hauptdiskussion | -0,27 % | |
5 | DPCM Capital Hauptdiskussion | -2,58 % | |
6 | GAMESTOP Hauptdiskussion | +0,71 % | |
7 | Zeta Global Holdings | +0,16 % | |
8 | TESLA MOTORS Hauptdiskussion | +7,36 % | |
9 | VALNEVA SE Hauptdiskussion | +11,70 % | |
10 | ROCK TECH LITHIUM Hauptdiskussion | +1,31 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | ATOS Hauptdiskussion | -15,15 % | |
2 | Lilium Aktie | +268,39 % | |
3 | BAYER Hauptdiskussion | -0,63 % | |
4 | GAMESTOP Hauptdiskussion | +0,71 % | |
5 | Zeta Global Holdings | +0,16 % | |
6 | TESLA MOTORS Hauptdiskussion | +7,36 % | |
7 | VALNEVA SE Hauptdiskussion | +11,70 % | |
8 | ROCK TECH LITHIUM Hauptdiskussion | +1,31 % | |
9 | DPCM Capital Hauptdiskussion | -2,58 % | |
10 | FREYR Battery Inc Registered Shs Hauptdiskussion | +16,02 % | Alle Diskussionen |